73694-15-2

Usage

Uses

Used in Anticancer Applications:
2'-Hydroxy-2,4,4',5,6'-pentamethoxychalcone is used as an anticancer agent for its inhibitory effects on the growth of certain cancer cells. It modulates various oncological signaling pathways, exerting inhibitory effects on tumor growth and progression.
Used in Anti-inflammatory Applications:
In the field of anti-inflammatory applications, 2'-hydroxy-2,4,4',5,6'-pentamethoxychalcone is used as a therapeutic agent for the treatment of inflammatory diseases due to its anti-inflammatory properties.
Used in Drug Development:
2'-Hydroxy-2,4,4',5,6'-pentamethoxychalcone is used in the development of new drugs for various medical conditions, leveraging its potential biological and pharmacological activities.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 2'-hydroxy-2,4,4',5,6'-pentamethoxychalcone is used as a key compound in the formulation of drugs targeting cancer and inflammatory diseases, due to its demonstrated biological activities and therapeutic potential.

Upstream product

• 480-66-0 2,4,6-trihydroxyacetophenone 
• 90-24-4 2-hydroxy-4,6-dimethoxyacetophenone 
• 4460-86-0 asaraldehyde 

Relevant academic research and scientific papers

Development of a novel nitric oxide (NO) production inhibitor with potential therapeutic effect on chronic inflammation

Inflammation is a complex biological response to stimuli. Activated macrophages induced excessively release of pro-inflammatory cytokines and mediators such as endogenous radical nitric oxide (NO) play a significant role in the progression of multiple inflammatory diseases. Both natural and synthetic chalcones possess a wide range of bioactivities. In this work, thirty-nine chalcones and three related compounds, including several novel ones, based on bioactive kava chalcones were designed, synthesized and their inhibitory effects on NO production in RAW 264.7 cells were evaluated. The novel compound (E)-1-(2′-hydroxy-4′,6′-dimethoxyphenyl)-3-(3-methoxy-4-(3-morpholinopropoxy)phenyl)prop-2-en-1-one (53) exhibited a better inhibitory activity (84.0%) on NO production at 10 μM (IC50 = 6.4 μM) with the lowest cytotoxicity (IC50 > 80 μM) among the tested compounds. Besides, western blot analysis indicated that compound 53 was a potent down-regulator of inducible nitric oxide synthase (iNOS) protein. Docking study revealed that compound 53 also can dock into the active site of iNOS. Furthermore, at the dose of 10 mg/kg/day, compound 53 could both significantly suppress the progression of inflammation on collagen-induced arthritis (CIA) and adjuvant-induced arthritis (AIA) models. In addition, the structure-activity relationship (SAR) of the kava chalcones based analogs was also depicted.